Abstract:The largest family of drug targets in clinical trials constitute of GPCRs (G-protein coupled receptors) which accounts for about 34% of FDA (Food and Drug Administration) approved drugs acting on 108 unique GPCRs. Factors such as readily identifiable conserved motif in structures, 127 orphan GPCRs despite various de-orphaning techniques, directed functional antibodies for validation as drug targets, etc. has widened their therapeutic windows. The availability of 44 crystal structures of unique receptors, unexplored non-olfactory GPCRs (encoded by 50% of the human genome) and 205 ligand receptor complexes now present a strong foundation for structure-based drug discovery and design. The growing impact of polypharmacology for complex diseases like schizophrenia, cancer etc. warrants the need for novel targets and considering the undiscriminating and selectivity of GPCRs, they can fulfill this purpose. Again, natural genetic variations within the human genome sometimes delude the therapeutic expectations of some drugs, resulting in medication response differences and ADRs (adverse drug reactions). Around ~30 billion US dollars are dumped annually for poor accounting of ADRs in the US alone. To curb such undesirable reactions, the knowledge of established and currently in clinical trials GPCRs families can offer huge understanding towards the drug designing prospects including “off-target” effects reducing economical resource and time. The druggability of GPCR protein families and critical roles played by them in complex diseases are explained. Class A, class B1, class C and class F are generally established family and GPCRs in phase I (19%), phase II(29%), phase III(52%) studies are also reviewed. From the phase I studies, frizzled receptors accounted for the highest in trial targets, neuropeptides in phase II and melanocortin in phase III studies. Also, the bioapplications for nanoparticles along with future prospects for both nanomedicine and GPCR drug industry are discussed. Further, the use of computational techniques and methods employed for different target validations are also reviewed along with their future potential for the GPCR based drug discovery.

Emerging Roles for the Orphan GPCRs, GPR37 and GPR37 L1, in Stroke Pathophysiology

Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target

Role of orphan G-protein coupled receptors in tissue ischemia: A comprehensive review

Exploring orphan GPCRs in neurodegenerative diseases

Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1

Orphan Receptor GPR88 As an Emerging Neurotherapeutic Target

Orphan G Protein-Coupled Receptors (gpcrs): Biological Functions and Potential Drug Targets

GPR37 modulates progenitor cell dynamics in a mouse model of ischemic stroke

G Protein–Coupled Receptor (GPCR) Expression in Native Cells: “Novel” endoGPCRs as Physiologic Regulators and Therapeutic Targets

Research Status of the Orphan G Protein Coupled Receptor 158 and Future Perspectives

Protective effects of GPR37 via regulation of inflammation and multiple cell death pathways after ischemic stroke in mice

Emerging roles of the G-protein-coupled receptor 37 in neurological diseases and pain

Orphan G protein-coupled receptors: the ongoing search for a home

Orphan GPR52 as an emerging neurotherapeutic target

Pathophysiological roles of G-protein-coupled receptor kinases

Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection

Advancements in therapeutically targeting orphan GPCRs

Neuro-psychopharmacological Perspective of Orphan Receptors of Rhodopsin (class A) Family of G Protein-Coupled Receptors

Novel Targets for Stroke Therapy: Special Focus on TRPC Channels and TRPC6

G-protein Coupled Receptors As Therapeutic Targets for Neurodegenerative and Cerebrovascular Diseases.

Protease-Activated Receptors (PARs): Biology and Therapeutic Potential in Perioperative Stroke